Search
for
Sort by
Research 30 of 34
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
- Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
- Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
- Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
- Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
- Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
- Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users
- An update of anti-viral treatment of COVID-19
- Do Anti-androgens Have Potential as Therapeutics for COVID-19?
- Drug repositioning approach to target viral and host cells in terms of COVID-19 treatment: A review of in vivo experiments and clinical studies
- Editor’s picks January 2021
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- COVID‐19, androgens, and androgenic alopecia
- Correlation Between Nongenomic Action of C19-Steroids and COVID-19 Severity
- Androgen deprivation therapy and hormonal status in men with COVID-19
- Reply to comment on: The Gabrin sign
- COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia
- Alopecia in patients with COVID-19: A systematic review and meta-analysis
- Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?
- Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
- The immune response to COVID‐19: Does sex matter?
- Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
- Roles of steroid receptors in the lung and COVID-19
- Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?
- Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients